Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug
Aymanjed / Pixabay

Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug

According to a press release from Alnylam Pharmaceuticals, the Massachusetts-based biopharmaceutical company has completed the submission of its New Drug Application (NDA) for givosiran — its experimental acute hepatic porphyria…

Continue Reading Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug
Encouraging Topline Data has Been Shared From a Phase 3 Study of a Drug for Acute Hepatic Porphyria
source: pixabay.com

Encouraging Topline Data has Been Shared From a Phase 3 Study of a Drug for Acute Hepatic Porphyria

Topline results have been shared from a Phase 3 study of the investigational drug givosiran in patients with acute hepatic porphyria. For more detailed information you can view the source…

Continue Reading Encouraging Topline Data has Been Shared From a Phase 3 Study of a Drug for Acute Hepatic Porphyria
A Widely Used Antifungal Drug Could be Effective For Treating Congenital Erthropoietic Porphyria
Alexas_Fotos / Pixabay

A Widely Used Antifungal Drug Could be Effective For Treating Congenital Erthropoietic Porphyria

According to a story from Medical Xpress, an international group of scientists from the US, France, and Spain may have discovered that an antifungal agent commonly used to treat skin…

Continue Reading A Widely Used Antifungal Drug Could be Effective For Treating Congenital Erthropoietic Porphyria